Headache diagnoses in patients with orofacial pain at a specialized pain center
https://doi.org/10.33667/2078-5631-2023-2-7-11
Abstract
Background. Headache and orofacial pain (OFP) are widespread at specialized pain centers. However, reliable data on their prevalence and co-occurrence are lacking, and prevalence of OFP in headache patients seems to be underestimated. The aim of this study was to evaluate the types of headache in patients with OFP and types of OFP in patients with headache.
Methods. We enrolled patients presenting with headache and/or OFP. Patients were examined by an experienced headache and pain specialist who questioned the patients about the presence of OFP. Depression was assessed with the Beck Depression Inventory (BDI-II), anxiety – with the Beck Anxiety Inventory (BAI). Bruxism was evaluated based on subject self-report.
Results. We recruited 310 patients: 177 (57%) patients with headache, 28 (9%) patients with OFP and 105 (34%) patients presenting with both types of pain. The prevalence of OFP in headache patients was 37.2%. Migraine was the most prevalent type of headache, while painful temporomandibular disorder (TMD) – the most prevalent form of OFP. Patients with PFP presented with a high prevalence of sleep and awake bruxism.
Conclusion. Migraine and pain-related TMD are the most prevalent diagnoses in a specialized pain center. OKI and OKI ACT are soluble forms of ketoprofen and reach peak concentration in 15 minutes. This enables faster onset of action compared to conventional NSAIDs and better tolerability. OKI and OKI ACT are recommended in the acute treatment of migraine with comorbid painful TMD.
About the Authors
E. A. Kislova
Family Doctor Clinic
Russian Federation
Russian Federation
Kislova Elena A., neurologist
Moscow
N. V. Latysheva
I. M. Sechenov First Moscow State Medical University (Sechenov Unversity); Alexander Vein Headache Clinic
Russian Federation
Russian Federation
Latysheva Nina V., DM Sci (habil.), professor of Dept of Nervous Diseases, Institute for Postgraduate Education
Moscow
E. G. Filatova
I. M. Sechenov First Moscow State Medical University (Sechenov Unversity); Alexander Vein Headache Clinic
Russian Federation
Russian Federation
Filatova Elena G., DM Sci (habil.), professor of Dept of Nervous Diseases, Institute for Postgraduate Education
Moscow
References
1. Silva T. B., Ortiz F. R., Maracci L. M., Silva G. B., Salbego R. S., Liedke G. S., Marquezan
2. M. Association among headache, temporomandibular disorder, and awake bruxism:
3. A cross-sectional study. Headache. 2022; 62 (6): 748–754.
4. Е. В. Фомичев, Е. Н. Ярыгина. Диагностика и лечение синдрома болевой дис-
5. функции височно-нижнечелюстного сустава. Вестник Волгоградского государ-
6. ственного медицинского университета. 2015. № 3 (55). С. 133–135.
7. E. V. Fomichev, E. N. Yarygin. Diagnosis and treatment of temporomandibular joint
8. pain dysfunction syndrome. Bulletin of the Volgograd State Medical University. 2015.
9. No. 3 (55). Pp. 133–135.
10. Kulkarni S., et al. Evaluating the effectiveness of nonsteroidal anti-inflammatory drug
11. for relief of pain associated with temporomandibular joint disorders: A systematic
12. review. Clin Exp Dent Res. 2020; 6 (1): 134–146.
13. Marmura M. J., Silberstein S. D., Schwedt T. J. The acute treatment of migraine in
14. adults: the American headache society evidence assessment of migraine pharmacotherapies.
15. Headache. 2015; 55 (1): 3–20.
16. Мигрень. Клинические рекомендации МЗРФ. 2021. https://cr.minzdrav.gov.ru/
17. schema/295_2 (Доступ 01/02/23)
18. Migraine. Clinical recommendations of the MZRF. 2021. https://cr.minzdrav.gov.ru/
19. schema/295_2 (Accessed 01/02/23)
20. Филатова Е. Г., Осипова В. В., Табеева Г. Р. и др. Диагностика и лечение мигрени:
21. рекомендации российских экспертов. Неврология, нейропсихиатрия, психо-
22. соматика. 2020; 12 (4): 4–14.
23. Filatova E. G., Osipova V. V., Tabeeva G. R. Diagnosis and treatment of migraine:
24. Recommendations of Russian experts. Neurology, neuropsychiatry, psychosomatics.
25. ; 12 (4): 4–14.
26. Panerai A. E., Lanata L., Ferrari M., et al. A new ketoprofen lysine salt formulation:
27. mg orodispersible granules. Trends Med 2012; 12 (4): 159–167.
28. Novelli R, Aramini A, Boccella S, Bagnasco M, Cattani F, Ferrari MP, Goisis G, Minnella
29. EM, Allegretti M, Pace V. Ketoprofen lysine salt has a better gastrointestinal
30. and renal tolerability than ketoprofen acid: A comparative tolerability study in the
31. Beagle dog. Biomed Pharmacother. 2022 Sep;153:113336.
32. OKI: Summary of Product Characteristics.
33. Natale F. Studio in soggetti volontari sani della biodisponibilità relativa e della farmacocinetica
34. di ketoprofen dopo somministrazione per via orale sotto forma di sale
35. di lisina in formulazione bustine di granulato (dose singola e ripetuta) e in forma di
36. ketoprofen acido formulato in capsule. Report Interno Dompè 1991.
37. Пилипович А. А., Данилов А. Б., Симонов С. Г. Боль в шее: причины и подходы
38. к лечению. РМЖ. 2012. С. 18.
39. Pilipovich A. A., Danilov A. B., Simonov S. G. Neck pain: causes and treatment approaches.
40. breast cancer. 2012. P. 18.
Review
For citations:
Kislova E.A., Latysheva N.V., Filatova E.G. Headache diagnoses in patients with orofacial pain at a specialized pain center. Medical alphabet. 2023;(2):7-11. (In Russ.) https://doi.org/10.33667/2078-5631-2023-2-7-11
Views:
421
Email this article 